FDA expands pediatric use of Bristol's HIV drug Sustiva

05/6/2013 | Drug Store News · RTT News

The FDA approved Bristol-Myers Squibb's Sustiva, or efavirenz, to treat HIV-1 patients ages 3 months to 3 years who weigh at least 7.7 pounds. The approval covers sprinkle administration when swallowing a capsule or tablet isn't possible. The drug was evaluated in three open-label trials involving 182 patients.

View Full Article in:

Drug Store News · RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA